

Innovative Health Initiative (IHI)

ENRIQUE ESQUIVEL, STRATEGY AND INNOVATION MANAGER



Introducing COCIR

COCIR is the European Trade Association representing

- Medical Imaging
- > Radiotherapy
- > Health ICT
- > Electromedical
 - Founded in 1959, COCIR is a non-profit association headquartered in Brussels (Belgium) with a China Desk based in Beijing since 2007. COCIR is also a founding member of <u>DITTA</u>, the Global Diagnostic Imaging, Healthcare IT and Radiation Therapy Trade Association.
 - Our industry leads in state-of-art advanced technology and provides integrated solutions covering the complete care cycle.



IHI - Innovative Health Initiative

General Introduction


The Innovative Health Initiative (IHI) is a new Joint Undertaking under Horizon Europe (HEU)

Cross-sectorial collaboration in health research & innovation, combining pharma and medtech

Successor of IMI, now with (general HEU) funding and IP conditions applicable to non-pharma companies


Five industry associations (COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe), being the Private Members, together with public partners, will pioneer healthcare innovation along the patient care continuum

Industry contribution (50%) is matched with EU funding (50%), representing a 2.4B program (2021-2027)



IHI: A public-private partnership





Collaboration extends to:

- Programming
- Financing
- Public and private partners collaborating in individual projects

What do associations do?



- Represent the respective healthcare industry sector vis-à-vis the EU Institutions and other stakeholders
- Provide support related to industry participation in IHI
- Work on IHI represents only one part of our activities, the function and work of associations is considerably more extensive
- The purpose, activities and membership rules are laid out in each membership's statutes
- We work with members (corporate and national associations) to ensure mutual visibility in/of IHI
- We represent our industries via direct membership and via national associations











Why participate in IHI?



IHI's objectives are set out in the legislation creating IHI.

The general objectives are to:

- turn health research and innovation into real benefits for patients and society;
- deliver safe, effective health innovations that cover the entire spectrum of care from prevention to diagnosis and treatment – particularly in areas where there is an unmet public health need;
- make Europe's health industries globally competitive;
- strategic commitment and investment in the long term;
- pre-competitive: no product around the corner;
- collaboratively building landscape for long term European research and healthcare;
- share and pool knowledge be part of long-term shaping of Europe;
- grant funding should not be driver for industry participation;
- most industrial engagement will be through in-kind contribution.




IHI Benefits

- Earmarked budget for R&I in healthcare, including medical device research & innovation
- Expected higher success rates for project proposals than in the general Horizon Europe programme
- COCIR members can directly influence the scientific priorities to be funded (through the Strategic Research Agenda and defining call topics in the Work Programme)
- Neutral platform to exchange ideas with other industry sectors, research funders, regulators, healthcare authorities, providers & professionals, academia & patients







What makes IHI different from regular Horizon Europe Calls?



- IHI equally associates the EC and Industry in selecting the topics... unlike HEU* where EC is the sole decider
- Each IHI project requires 50% of the budget from industry...unlike HEU where there is no minimum funding from industry
- IHI aims at delivering (direct and concrete) impact on the healthcare delivery
- The average budget of an IHI project is usually >15 M€, sometimes much more (ex: 60 M€)... unlike HEU projects with budget on average <15 M€

Where do topics come from?



- 1. It's a collaborative process between all partners with lots of different inputs
- 2. For associations inputs can include, for example:
 - Feedback from association members (companies <u>and</u> national associations)
 - Scientific/technical/healthcare conferences related to our sector
 - External proposed ideas (e.g. theranostics)
 - Science and Innovation Panel
 - Synergies with other EU initiatives and goals (e.g. EU Mental Health Strategy, Green Deal, non-animal approaches: continuous dialogue with EC)
 - Experiences from previous calls (e.g. biomarkers)
- 1. Members work together to identify areas that if addressed would contribute to IHI's objectives
- 2. Critical to assess industry willingness to invest in-kind contributions
- 3. Mapping what type of approach could best contribute to address the need

2 types of calls



Single-stage

- Broad topics, not specific to one single product/technology/solution
- Private Members apply simultaneously with Public Members in <u>mixed</u> <u>consortia</u> and co-develop their proposal for the single application
- Private Members can receive funding, but Pharma companies abstain from requesting funding
- In-kind contributions by private and contributing partners must be secured during proposal preparation

Two-stage

- Targeted topics suited for a single, unified approach
- Industry and public consortia are formed separately
- Public consortia submit competing short proposals in the first round of the call
- A single top-ranked public consortium is selected and paired up with the industry consortium to prepare a joint, full proposal
- Private Members are not eligible for funding and no funding will be made available for companies with > 500M EUR annual turnover
- Industry contributions are committed prior to call launch: no need for public participants to secure further in-kind contributions

Call 3 (single-stage): 2 Digital Health Topics



- Project PREDICTOM (Nov 2023-Oct 2027): prediction of Alzheimer's disease using an Al-driven screening platform.
- Seeks to address gaps in early detection by developing a scalable, open-source biomarker screening platform for dementia risk.
- Will combine at-home samples (blood, saliva, stool) with advanced technologies like MRI, EEG, eye tracking, blood-based biomarkers, and Al-driven analysis to identify high-risk individuals and enable tailored interventions.
- Will provide evidence for population-wide screening and establish clinical guidelines to improve healthcare practices.
- Total contributions (EU, IND, contributing partners): 20 252 255€.

- Project IMPROVE (Dec 2023-Nov 2028): framework to improve the integration of patientgenerated health data to facilitate value-based healthcare.
- Uses **patient-generated health data** (**PGHD**) from m-health and e-health tools to better understand real-life challenges of patients with chronic diseases.
- Seeks to complement and enhance existing patient-centered outcome measures using these data.
- Aims to improve patient-centered outcomes by developing a platform for smarter use of this data, focusing on 10 use cases across five disease areas: ophthalmology, oncology, cardiovascular disease, chronic inflammation, and neurology.
- > Total contributions (EU, IND): 18 759 800€.

THANK YOU